Nkarta Reports Q1 2026 Financial Results with $27.8 Million Net Loss

Nkarta, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $27.8 million, a decrease from the $32.0 million loss recorded in the same period of the previous year. The company's total operating expenses for the quarter were $30.9 million, down from $36.6 million in Q1 2025, primarily due to a significant reduction in general and administrative expenses, which fell from $12.4 million to $5.9 million. This decrease was largely attributed to lower personnel costs following a reduction in force in March 2025, which resulted in severance expenses of $5.1 million in the prior year.

Research and development expenses increased slightly to $25.0 million from $24.2 million year-over-year, driven by higher clinical spending related to Nkarta's lead product candidate, NKX019, which is being developed for autoimmune diseases. The company reported a $2.1 million increase in program costs, offset by lower manufacturing and materials expenses. Interest income also declined to $2.8 million from $4.4 million, reflecting lower average investment balances and interest rates.

As of March 31, 2026, Nkarta's cash, cash equivalents, restricted cash, and investments totaled $266.7 million, a decrease from $282.5 million at the end of 2025. The company has not generated any revenue from product sales and has accumulated a deficit of $676.1 million since its inception. Nkarta's management indicated that the current cash reserves are expected to support operations for at least the next twelve months, although they anticipate needing additional capital to fund ongoing research and development activities.

Strategically, Nkarta is focused on advancing its NK-cell therapy platform, particularly NKX019, which is currently undergoing clinical trials for various autoimmune conditions. The company has made significant progress in its clinical trials, including protocol amendments approved by the FDA that allow for outpatient administration of NKX019. Additionally, Nkarta has streamlined its enrollment process for clinical trials, which may enhance patient recruitment and data collection.

Looking ahead, Nkarta plans to continue its clinical development efforts while managing costs. The company may seek additional funding through equity or debt financing, as well as potential collaborations, to support its long-term development strategy. The success of Nkarta's product candidates remains uncertain, and the company faces various risks associated with clinical trials and regulatory approvals, which could impact its financial performance and operational plans.